Novartis AG

Novartis’ dual thrust—Fabhalta’s 49% kidney‑slowdown efficacy and a $2 bn Excellergy anti‑IgE deal—boosts its portfolio, revenue outlook and investor confidence.

Novartis secures FDA approval for Cosentyx in children ≥12 with severe hidradenitis suppurativa, opening new therapeutic and market opportunities.

Novartis releases real‑world evidence boosting Pluvicto’s use for metastatic prostate cancer and faces shareholder‑driven CEO compensation review.

Novartis’s Q4 2025 earnings dip masks solid sales growth and a $2 billion‑plus Avidity Biosciences deal that could drive future oncology breakthroughs.

Novartis AG’s resilient stock performance, JPMorgan’s overweight rating, and a new U.S. drug‑price agreement show steady long‑term value amid market gains.

Novartis shows strong momentum in its Cardiovascular, Renal & Metabolic pipeline, revealing Phase III, real‑world and early‑stage data that reinforce its leadership and market potential.

Novartis AG navigates turbulent market conditions, including US trade tensions and tariffs, while pursuing strategic acquisitions to bolster its portfolio and drive innovation.

Novartis AG has achieved a decade of consistent growth, with a 12% revenue increase in Q2 2025, driven by innovation and strategic leadership, positioning the company for future success in the pharmaceutical industry.